Scientific basis for the combination of tegafur with uracil

Yoshihiko Maehara

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Fujii et al reported that Uracil potentiated the antitumor activity of fluorouracil (5-FU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur). This effect was due to inhibition of the degradation of 5-FU, yet the phosphorylation of 5-FU was unaffected. The molar ratio of tegafur and uracil was 1:4, a combination that has since been widely prescribed in Japan for the treatment of cancer patients. We present here our experimental and clinical results when investigating the antineoplastic effects of this combination of drugs - known as UFT - and provide evidence that UFT is an effective treatment for patients with cancer.

Original languageEnglish
Pages (from-to)14-21
Number of pages8
JournalOncology
Volume11
Issue number9 SUPPL. 10
Publication statusPublished - Nov 13 1997

Fingerprint

Tegafur
Uracil
Fluorouracil
Antineoplastic Combined Chemotherapy Protocols
Neoplasms
Japan
Phosphorylation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Maehara, Y. (1997). Scientific basis for the combination of tegafur with uracil. Oncology, 11(9 SUPPL. 10), 14-21.

Scientific basis for the combination of tegafur with uracil. / Maehara, Yoshihiko.

In: Oncology, Vol. 11, No. 9 SUPPL. 10, 13.11.1997, p. 14-21.

Research output: Contribution to journalArticle

Maehara, Y 1997, 'Scientific basis for the combination of tegafur with uracil', Oncology, vol. 11, no. 9 SUPPL. 10, pp. 14-21.
Maehara Y. Scientific basis for the combination of tegafur with uracil. Oncology. 1997 Nov 13;11(9 SUPPL. 10):14-21.
Maehara, Yoshihiko. / Scientific basis for the combination of tegafur with uracil. In: Oncology. 1997 ; Vol. 11, No. 9 SUPPL. 10. pp. 14-21.
@article{fced614ec26642c0a258fe9d8cc9d78d,
title = "Scientific basis for the combination of tegafur with uracil",
abstract = "Fujii et al reported that Uracil potentiated the antitumor activity of fluorouracil (5-FU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur). This effect was due to inhibition of the degradation of 5-FU, yet the phosphorylation of 5-FU was unaffected. The molar ratio of tegafur and uracil was 1:4, a combination that has since been widely prescribed in Japan for the treatment of cancer patients. We present here our experimental and clinical results when investigating the antineoplastic effects of this combination of drugs - known as UFT - and provide evidence that UFT is an effective treatment for patients with cancer.",
author = "Yoshihiko Maehara",
year = "1997",
month = "11",
day = "13",
language = "English",
volume = "11",
pages = "14--21",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9 SUPPL. 10",

}

TY - JOUR

T1 - Scientific basis for the combination of tegafur with uracil

AU - Maehara, Yoshihiko

PY - 1997/11/13

Y1 - 1997/11/13

N2 - Fujii et al reported that Uracil potentiated the antitumor activity of fluorouracil (5-FU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur). This effect was due to inhibition of the degradation of 5-FU, yet the phosphorylation of 5-FU was unaffected. The molar ratio of tegafur and uracil was 1:4, a combination that has since been widely prescribed in Japan for the treatment of cancer patients. We present here our experimental and clinical results when investigating the antineoplastic effects of this combination of drugs - known as UFT - and provide evidence that UFT is an effective treatment for patients with cancer.

AB - Fujii et al reported that Uracil potentiated the antitumor activity of fluorouracil (5-FU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur). This effect was due to inhibition of the degradation of 5-FU, yet the phosphorylation of 5-FU was unaffected. The molar ratio of tegafur and uracil was 1:4, a combination that has since been widely prescribed in Japan for the treatment of cancer patients. We present here our experimental and clinical results when investigating the antineoplastic effects of this combination of drugs - known as UFT - and provide evidence that UFT is an effective treatment for patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=0030833056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030833056&partnerID=8YFLogxK

M3 - Article

C2 - 9348561

AN - SCOPUS:0030833056

VL - 11

SP - 14

EP - 21

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9 SUPPL. 10

ER -